Product Development

Pulmosat has spent years in developing a completely new pulmonary disease treatment molecule. When this molecule is delivered via a unique delivery mechanism (developed in association with a Swedish/Dutch Company), improved (up to 10 x) delivery of Molecule Psat to the alveolar (gas exchange) area of the lungs is obtained, compared to current nebuliser methods. Direct delivery of the molecule to the area of lung affliction represents the future of lung disease management.

Safer, more efficient drug delivery with virtually no side-effects.